A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric Practices

A Prospective, Multicenter, Open-Label Study of Aripiprazole in the Management of Patients With Schizophrenia in General Psychiatric Practices (Broad Effectiveness Trial With Aripiprazole- BETA)

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00237939

Enrollment

1200

Registered

2005-10-13

Start date

2002-09-30

Completion date

2006-11-30

Last updated

2013-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Brief summary

The purpose of this clinical research study is to evaluate if Aripiprazole will prove to be effective, safe and well tolerated in the treatment of patients with schizophrenia who are treated in a general psychiatric setting.

Interventions

DRUGAripiprazole

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Clinical DSM-IV diagnosis of schizophrenia * Patients being managed as outpatients, for whom an alteration in medication is clinically reasonable or initiation of antipsychotics is required

Exclusion criteria

* Risk of committing suicide, diagnosis of schizoaffective disorder, bipolar disorder, depression with psychotic syptoms, or organic brain syndromes * Prisoners or subjects compulsory detained

Design outcomes

Primary

Measure	Time frame
Clinical Global Impression-Improvement at endpoint	—

Secondary

Measure	Time frame
Patients' and caregivers' medication preference	—

Countries

Belgium, France, Netherlands, Portugal, Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026